Literature DB >> 17227898

Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program.

Matthew J Hayat1, Nadia Howlader, Marsha E Reichman, Brenda K Edwards.   

Abstract

An overview of cancer statistics and trends for selected cancers and all sites combined are given based on data from the Surveillance, Epidemiology, and End Results Program. Median age at diagnosis for all sites combined shows a 2-year increase from 1974 through 1978 to 1999 through 2003. Changes in cancer incidence rates from 1975 through 2003 are summarized by annual percent change for time periods determined by joinpoint regression analysis. After initial stability (1975-1979), incidence rates in women for all cancer sites combined increased from 1979 through 2003, although the rate of increase has recently slowed. For men, initial increases in all cancer sites combined (1975-1992) are followed by decreasing incidence rates (1992-1995) and stable trends from 1995 through 2003. Female thyroid cancer shows continued increasing incidence rates from 1981 through 2003. Blacks have the highest incidence and mortality rates for men and women for all cancer sites combined. Based on 2001 through 2003 data, the likelihood of developing cancer during one's lifetime is approximately one in two for men and one in three for women. Five-year relative survival for all stages combined (1996-2002) ranges from 16% for lung to 100% for prostate cancer patients. Cancer survival varies by stage of disease and race, with lower survival in blacks compared with whites. The risk of developing subsequent multiple primary cancers varies from 1% for an initial liver primary diagnosis to 16% for initial bladder cancer primaries. The impact on the future U.S. cancer burden is estimated based on the growing and aging U.S. population. The number of new cancer patients is expected to more than double from 1.36 million in 2000 to almost 3.0 million in 2050.

Entities:  

Mesh:

Year:  2007        PMID: 17227898     DOI: 10.1634/theoncologist.12-1-20

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  334 in total

1.  Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis.

Authors:  Deirdre P Cronin-Fenton; Liam J Murray; David C Whiteman; Chris Cardwell; Penelope M Webb; Susan J Jordan; Douglas A Corley; Linda Sharp; Jesper Lagergren
Journal:  Eur J Cancer       Date:  2010-04-22       Impact factor: 9.162

Review 2.  A review of sentinel lymph node biopsy for thin melanoma.

Authors:  K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan
Journal:  Ir J Med Sci       Date:  2014-11-01       Impact factor: 1.568

3.  An age-period-cohort analysis of cancer incidence among the oldest old, Utah 1973-2002.

Authors:  Heidi A Hanson; Ken R Smith; Antoinette M Stroup; C Janna Harrell
Journal:  Popul Stud (Camb)       Date:  2014-11-14

Review 4.  Breast cancer and fertility preservation.

Authors:  S Samuel Kim; Jennifer Klemp; Carol Fabian
Journal:  Fertil Steril       Date:  2011-01-26       Impact factor: 7.329

5.  Impact of partial-volume effect correction on the predictive and prognostic value of baseline 18F-FDG PET images in esophageal cancer.

Authors:  Mathieu Hatt; Adrien Le Pogam; Dimitris Visvikis; Olivier Pradier; Catherine Cheze Le Rest
Journal:  J Nucl Med       Date:  2012-01       Impact factor: 10.057

6.  Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer.

Authors:  Manfred Kaufmann; Thomas Karn; Eugen Ruckhäberle
Journal:  World J Surg       Date:  2012-07       Impact factor: 3.352

Review 7.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

8.  Second malignant neoplasms in patients with Cowden syndrome with underlying germline PTEN mutations.

Authors:  Joanne Ngeow; Kim Stanuch; Jessica L Mester; Jill S Barnholtz-Sloan; Charis Eng
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

9.  Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Authors:  Mohamed A Hamza; Jacob J Mandel; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Vinay K Puduvalli; John F DeGroot
Journal:  J Neurooncol       Date:  2014-05-07       Impact factor: 4.130

10.  Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.

Authors:  Jieqiong Liu; Wen Jiang; Kai Mao; Yi An; Fengxi Su; Betty Y S Kim; Qiang Liu; Lisa K Jacobs
Journal:  Breast Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.